Treatment Centers and Clinical Trials
You can restrict your search to only Treatment Centers or only Clinical Trials by checking the Treatment Center or Clinical Trial checkbox under TYPE. Use the Zoom-In (+ sign on the lower right of the map) to enlarge the map area to find your preferred location. To search for a Treatment Center or Clinical Trial, click on the red map pin for the name of the facility. Click on the name of the facility for more details.
Location
Treatments/Services
Type
IU Simon Cancer Center
Beth Israel Deaconess Medical Center
The University of Kansas Hospital
Skin Cancer Center - HELIOS Klinikum Krefeld
Miami Cancer Institute BHSF
University of North Carolina Medical Center
Hospital Universitario 12 de Octubre
St. Thomas Hospital - St Johns Department of Dermatology
OU Physicians
Mayo Clinic - Arizona Campus
Yale University School of Medicine
University Dermatology and Skin Cancer Center
Medical University of Vienna
Columbia University Irving Medical Center - Cutaneous Lymphoma Center
University Dermatology Consultants, Inc.
Cutaneous Lymphoma Multidisciplinary Clinic - Lisbon
John Theurer Cancer Center at HUMC
Huntsman Cancer Institute
University of Virginia-Emily Couric Clinical Cancer Center
Washington University Medical Center - Siteman Cancer Center
Fondazione IRCCS Ca' Granda
Center for Cutaneous Oncology at Dana Farber/Brigham Cancer Institute
Rush University Medical Center
Charité University of Medicine Berlin - Skin Cancer Center
Cleveland Clinic - Indian River Hospital
University of Iowa Hospitals & Clinics
Semmelweis Medical School
Roswell Park Comprehensive Cancer Center
Johns Hopkins Dermatology
Winship Cancer Institute - Emory University
Northwestern Medicine
UAMS Cancer Center
Medical University of Graz
Dartmouth-Hitchcock Norris Cotton Cancer Center
Tulane University School of Medicine
Spedali Civili di Brescia
Memorial Sloan Kettering Cancer Center
UCHealth - University of Colorado Cancer Center - Anschutz
University of Texas Southwestern Medical Center
Saint Louis University Cancer Center
Mayo Clinic - Florida
Boston Medical Center - Cutaneous Oncology Program
ROCHESTER SKIN LYMPHOMA MEDICAL GROUP, PLLC
Hospital Dresden-Friedrichstadt
Moffitt Cancer Center
University of California, San Francisco
University of Essen - Department of Dermatology
OSU Comprehensive Cancer Center
MUSC Cutaneous Lymphoma Clinic
Atrium Health Wake Forest Baptist
University of Michigan Medical Center
Westmead Hospital - University of Sydney
INOVA Melanoma and Skin Oncology Center
Fred Hutch Cancer Center
Rambam Medical Center
University Hospital Zurich - Department of Dermatology
Duke Cutaneous T-Cell Lymphoma Clinic and Research Center
University of Rochester - Wilmot Cancer Institute
Chao Family Comprehensive Cancer Center
Clinical Cancer Center, Froedtert Hospital
Jefferson Cutaneous Lymphoma Clinic
OhioHealth Physician Group - Hematology/Oncology
Helsinki University Hospital
University of Texas MD Anderson Cancer Center
University of Alabama Medical Center
University Medical Centre - Mannheim
Johann Wolfgang Goethe-University Frankfurt
Oregon Health & Science University (OHSU)
Vanderbilt University Medical Center
Henry Ford Hospital - Cutaneous Lymphoma Program
Peter MacCallum Cancer Centre
Massachusetts General Hospital
The Warren Alpert Medical School of Brown University, Department of Dermatology
Rabin Medical Center
Cutaneous Lymphoma Clinic - Kimberly and Eric J. Waldman Dept of Dermatology
Levine Cancer Institute
University of Pittsburgh Medical Center
City of Hope National Medical Center
Cleveland Clinic
Penn Cutaneous Lymphoma Program
Calgary Cutaneous Lymphoma Program
Hôtel-Dieu - CHU de Nantes
NYU Grossman School of Medicine
University Hospitals of Cleveland
Friedrich Schiller University - Hospital Jena
Emil P. Bisaccia, MD, Center for Photopheresis at Morristown Medical Center
Stanford Medical Center (Multidisciplinary Cutaneous Lymphoma Clinic)
University of Wisconsin - Madison
Extracorporeal Photopheresis in Sezary Syndrome (ECP)
Brief Summary:
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Brief Summary
This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.
Website: https://clinicaltrials.gov/study/NCT05010005
Sponsor: Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Permitted histologies include:
Duvelisib + Nivolumab for the Treatment of MF and SS
Brief Summary:
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Brief Summary
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Website: https://clinicaltrials.gov/study/NCT03587844
Sponsors: Memorial Sloan Kettering Cancer Center
Ritlecitinib in CTCL
Brief Summary
The purpose of this research study is to evaluate the effectiveness and safety of Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a rare type of cancer that starts in the white blood cells and eventually can result in rashes or tumors in the skin. This study includes a 24 week Treatment Period and a 24 week Follow-up Period. This study will involve physical examinations, visual assessments, laboratory tests, PET-CT scans, electrocardiograms, photographs of your skin, skin biopsies, and hearing tests.
Dose-Escalation Trial Evaluating CPI-818
Brief Summary:
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug. This trial is composed of dose escalation and dose expansion cohorts.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Pembrolizumab in Combination With Gemcitabine in People With Advanced MF or SS
Brief Summary
The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Website: https://clinicaltrials.gov/study/NCT04960618#contacts-and-locations
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTC
Brief Summary:
This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light (RW-HPN
Brief Summary
The goal of this clinical trial is to assess the benefit of continuous treatment with synthetic hypericin ointment (HyBryte) and visible light in patients with mycosis fungoides for up to 12 months (54 weeks). Funding Source: FDA OOPD.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Pembrolizumab - Stage IB-IV Mycosis Fungoides
Brief Summary:
This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Ly
Brief Summary
Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Brief Summary:
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Brief Summary
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.
Phase 1 Trial of ST-001 nanoFenretinide
Description
Real World Observational Study of Poteligeo in Adult Patients With MF and SS
Brief Summary
This is a prospective, observational, non-interventional, international, multi-center, mixed methods study that will involve the integration of quantitative and qualitative data in patients with MF/SS treated with Poteligeo.
For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.